PT  - JOURNAL ARTICLE
AU  - Prasad, Kalpna
AU  - Bonavia, Grant
TI  - Phosphorus 32 radiosynovectomy revisited
DP  - 2017 May 01
TA  - Journal of Nuclear Medicine
PG  - 961--961
VI  - 58
IP  - supplement 1
4099  - http://jnm.snmjournals.org/content/58/supplement_1/961.short
4100  - http://jnm.snmjournals.org/content/58/supplement_1/961.full
SO  - J Nucl Med2017 May 01; 58
AB  - 961Objectives: Radio-synovectomy (RSV) is a well-established Nuclear Medicine (NM) procedure in certain European countries. In Germany, RSV is the 2nd most common NM therapy with about 40,000-60,000 joint treatments per year [1]. Despite its favorable results in chronic synovitis [2], safety profile [3], well established procedure guidelines [4] and long lasting pain relief compared to corticosteroid injections [5,6], the utilization of RSV in the United States is limited. This may be due to a number of factors which include: lack of awareness of therapeutic potential among referring physicians, limited procedure experience, insufficient coordination among NM physicians and interventional radiologists, limited availability of radio therapeutic agents, problems with reimbursement and concerns about radiation safety. The objective of this educational poster is: 1) To educate physicians about the potential of Phosphorus-32 (32-P) RSV as a viable option for treating severe refractory synovitis from diseases such as Pigmented Villonodular Synovitis (PVNS) and arthritis among others. 2) To discuss current usage, radiation risks, safety concerns, and techniques to minimize these risks. 3) To present a current 32-P RSV protocol for use in adult patients. 4) Share our recent experience with 32-P RSV.Methods: An overview of 32-P radio pharmacy and mechanism of action for RSV is presented. A literature review of 32-P chromic phosphate in RSV is performed in order to provide background on indications and practices. Recent experience of the 32-P RSV procedure performed in our institution is shared.Results: After reviewing this educational exhibit, the readers will:Better understand the 32-P chromic phosphate radiotherapeutic agent and its application in RSV for severe refractory synovitis from diseases such as PVNS, arthritis and others.Be able to discuss risks and benefits, and radiation exposure from the RSV procedure.Become familiar with a procedure protocol which can be easily adopted for use in their respective institution.Conclusion: Severe synovitis may be refractory to standard treatment modalities. 32-P RSV offers a viable therapeutic option in selected patients. Patient selection involves discussion of risks and benefits of therapy utilizing a safe and effective procedure protocol [7,8,9,10] such as one presented in this poster. Research Support: